Premium
Human B cell activation: Selective sensitivity of the early stages to calcium channel‐blocking drugs
Author(s) -
Dugas Bernard,
Vazquez Aimé,
Delfraissy JeanFrançois,
Gérard JeanPhilippe,
Rannou MarieThérèse,
Galanaud Pierre
Publication year - 1986
Publication title -
european journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.272
H-Index - 201
eISSN - 1521-4141
pISSN - 0014-2980
DOI - 10.1002/eji.1830160210
Subject(s) - calcium channel , biology , calcium , verapamil , nitrendipine , cell growth , voltage dependent calcium channel , microbiology and biotechnology , pharmacology , biochemistry , medicine
Abstract The importance of Ca 2+ in the early events of lymphocyte activation has been suggested by several studies. We examined the effect of calcium channel‐blocking drugs (verapamil and nitrendipine) on the progression of human B cells through their activation cycle. Our results show that these drugs suppress the anti‐μ‐induced human B cell proliferation and interfere with the early events of the B cell activation in a dose‐dependent fashion. This suppression correlates with a marked decrease in anti‐μ‐induced 45 Ca 2+ uptake. Calcium channel‐blocking drugs inhibit the anti‐μ‐induced uridine incorporation and the appearance of the activation marker defined by the 4F2 monoclonal antibody. Calcium channel‐blocking drugs also inhibit B cell proliferation induced by the costimulation with anti‐μ antibody and B cell growth factor (BCGF). However, this inhibition takes place at the early (anti‐μ‐dependent) stage of B cell activation: the BCGF‐dependent proliferation of in vitro anti‐μ‐activated B cells is only marginally inhibited. Finally the proliferation of Epstein‐Barr virus‐infected B cell lines is resistant to the effect of calcium channel‐blocking drugs.